1989
DOI: 10.1200/jco.1989.7.2.245
|View full text |Cite
|
Sign up to set email alerts
|

High-dose thiotepa with autologous bone marrow transplantation for metastatic malignant melanoma: results of phase I and II studies of the North American Bone Marrow Transplantation Group.

Abstract: We evaluated thiotepa in escalating dose in a broad phase I and II study using cryopreserved autologous bone marrow transplantation to assure hematopoietic recovery. Thiotepa was administered intravenously (IV) over two hours daily for three consecutive days followed in three to four days by marrow transplantation. The daily dose ranged from 60 to 525 mg/m2 (total dose, 180 to 1,575 mg/m2). A total of 71 patients with malignant melanoma were treated. Forty-three patients (61%) had received prior cytotoxic ther… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

0
8
0

Year Published

1990
1990
2015
2015

Publication Types

Select...
7
2
1

Relationship

0
10

Authors

Journals

citations
Cited by 35 publications
(8 citation statements)
references
References 9 publications
0
8
0
Order By: Relevance
“…Owing to its apparent benefit as a single agent against breast cancer in early NSABP adjuvant therapy trials [25] and its almost 20-fold increase potential for HDCT with Hematopoitic stem cell transplant (HSCT) [26,27] thiotepa became an integral component of many HDCT regimens [28,29].…”
Section: Discussionmentioning
confidence: 99%
“…Owing to its apparent benefit as a single agent against breast cancer in early NSABP adjuvant therapy trials [25] and its almost 20-fold increase potential for HDCT with Hematopoitic stem cell transplant (HSCT) [26,27] thiotepa became an integral component of many HDCT regimens [28,29].…”
Section: Discussionmentioning
confidence: 99%
“…The cyclophosphamide, carmustine and etoposide (CBV) regimen initially reported by Spitzer et al [27] has somewhat lower doses than the BCNU, etoposide and cyclophosphamide regimens that we used and has been employed as a preparative regimen for allogeneic transplantation [28]. Highdose cyclophosphamide with total body irradiation [29] or ThioTEPA 900 mg/m2 are considered to be myeloablative [15,30] and were used safely in this cur rent study with refrigeration storage of bone marrow.…”
Section: Discussionmentioning
confidence: 99%
“…They are normally classified as due to CNS infections, metabolic encephalopathies or thrombotic and haemorraghic cerebrovascular events. Also, they may be related to neurotoxicity of drugs used in the conditioning regimens (Sureda et al , 1989; Wolff et al , 1989), to immunosuppressives, such as cyclosporine (Reece et al , 1991) and steroids (Patchell, 1994), or to antimicrobials and antifungals for the treatment of infections (Pavletic et al , 1996).…”
Section: Neurologicalmentioning
confidence: 99%